C4X Discovery renews collaboration with Evotec AG

Manchester and London, UK, 18 December, 2014 – C4X Discovery (C4XD), a leader in rational drug discovery and design, announced today that it has extended its research collaboration agreement with Evotec, under which C4XD's proprietary NMR-based technology and conformational design expertise is applied across a number of Evotec's pre-clinical therapeutic projects to enhance lead discovery and hit identification.

C4XD has the only technology in the world that can generate accurate, experimentally-derived dynamic solution 3D structures of drug molecules in just a matter of days, helping to accelerate product development. It can be used in conjunction with existing technologies for structure-based drug design and can make a particularly high impact when protein crystallography is not routinely available, as is the case for GPCRs and ion channels.

The technology can also be applied to help identify and generate novel crystal polymorph forms, with exciting potential applications in the life cycle management of existing branded pharmaceuticals.

Piers Morgan, CEO of C4X, said "We are delighted to renew and extend our partnership with Evotec, a global leader in high-quality drug discovery solutions. This collaboration has generated valuable data underpinning the advantages and benefits of C4XD's technology."

Dr Mario Polywka, Chief Operating Officer of Evotec, commented: "We are pleased to continue working with C4XD and are excited by the progress so far with this alliance. C4XD has a highly innovative platform technology which complements our strong research base to accelerate product development."